• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors.

    "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term success."

    "I'm honored to join Bright Peak as an Independent Board Member," said Mr. Schmid. "I look forward to collaborating with the leadership team and fellow Directors in support of the company's mission of advancing breakthrough immunotherapies to patients with cancer."

    Mr. Schmid brings more than 35 years of financial and senior management experience in the biotechnology industry. As a Chief Financial Officer, he has raised over $900 million through private and public equity and debt financings. He has guided two companies through successful IPOs as a CFO, and over the course of the last ten years, he has been involved in six additional IPOs as an independent board member.

    He currently serves on the Boards of AnaptysBio (NASDAQ:ANAB), Design Therapeutics (NASDAQ:DSGN), Poseida Therapeutics (NASDAQ:PSTX), and Xeris Pharmaceuticals (NASDAQ:XERS), as well as the SPAC Helix Acquisition (NASDAQ:HLXA), acting as Audit Chair for each. He is also a Board Member of Forge Therapeutics and Speak, Inc.

    Previously, Mr. Schmid was CFO of Auspex Pharmaceuticals, which he took public in 2014 and later sold to Teva for $3.5 billion. He also co-founded Trius Therapeutics in 2004, serving as CFO through its IPO and eventual acquisition by Cubist Pharmaceuticals for over $700 million. Before Trius, he was CFO of GeneFormatics and Endonetics (acquired by Medtronic) as well as an Associate with Idanta Partners, a venture capital firm, Vice President at HomeFed Bank and a Financial Analyst for Manufacturers Hanover (now part of J.P. Morgan) in New York. He is a past President and a past board member of the San Diego Venture Group. Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.

    About Bright Peak Therapeutics

    Bright Peak Therapeutics is a clinical-stage biotechnology company pioneering multifunctional immunotherapies to treat cancer. Leveraging innovative protein engineering and a proprietary chemical conjugation platform, Bright Peak is building a robust pipeline of first-in-class multifunctional molecules. Its lead program, BPT567—a bifunctional PD1-IL18 immunoconjugate—is currently in Phase 1/2a clinical trials. Backed by leading healthcare investors, Bright Peak operates from its dual locations in San Diego, CA ,and Basel, Switzerland. For more information, visit www.brightpeaktx.com.

    Contact:

    [email protected]



    Primary Logo

    Get the next $ANAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANAB
    $DSGN
    $PSTX
    $XERS

    CompanyDatePrice TargetRatingAnalyst
    Xeris Biopharma Holdings Inc.
    $XERS
    8/12/2025$10.00Buy
    H.C. Wainwright
    AnaptysBio Inc.
    $ANAB
    6/4/2025$38.00Neutral → Buy
    H.C. Wainwright
    AnaptysBio Inc.
    $ANAB
    2/4/2025$25.00Outperform
    Wolfe Research
    AnaptysBio Inc.
    $ANAB
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    Poseida Therapeutics Inc.
    $PSTX
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    AnaptysBio Inc.
    $ANAB
    12/2/2024Buy → Neutral
    BTIG Research
    Xeris Biopharma Holdings Inc.
    $XERS
    11/11/2024$3.00Overweight → Neutral
    Piper Sandler
    AnaptysBio Inc.
    $ANAB
    7/22/2024$55.00Buy
    H.C. Wainwright
    More analyst ratings

    $ANAB
    $DSGN
    $PSTX
    $XERS
    SEC Filings

    View All

    AnaptysBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ANAPTYSBIO, INC (0001370053) (Filer)

    9/29/25 4:29:55 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by AnaptysBio Inc.

    SCHEDULE 13G - ANAPTYSBIO, INC (0001370053) (Subject)

    9/23/25 4:00:15 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Xeris Biopharma Holdings Inc.

    144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

    9/11/25 4:24:26 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $DSGN
    $PSTX
    $XERS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

    Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29

    9/29/25 4:05:49 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

    SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14. The event will include Joseph A. Murray, M.D., professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology at the Mayo Clinic, along with members of the Anaptys management team. The event will cover: ANB033's mechanism of action, an antagonist of the CD122 receptorPreclinical data and initial Phase 1a data in healt

    9/29/25 4:05:46 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Design Therapeutics Appoints Justin Gover to Board of Directors

    CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two decades, from inception through its strategic $7 billion acquisition by Jazz Pharmaceuticals in 2021. During his tenure, GW grew into a fully integrated global biotech organization and

    9/10/25 4:01:00 PM ET
    $CMPS
    $DSGN
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $DSGN
    $PSTX
    $XERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Xeris Biopharma with a new price target

    H.C. Wainwright resumed coverage of Xeris Biopharma with a rating of Buy and set a new price target of $10.00

    8/12/25 8:02:13 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00

    6/4/25 7:31:04 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on AnaptysBio with a new price target

    Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00

    2/4/25 6:58:43 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $DSGN
    $PSTX
    $XERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Mcculloch Kevin bought $109,475 worth of shares (25,000 units at $4.38), increasing direct ownership by 1% to 1,708,585 units (SEC Form 4)

    4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

    6/16/25 4:26:02 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/2/25 6:17:02 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    8/16/24 12:04:31 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $DSGN
    $PSTX
    $XERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Orwin John A converted options into 1,300 shares, increasing direct ownership by 14% to 10,665 units (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    9/17/25 4:02:23 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Mcculloch Kevin disposed of 2,000 shares (SEC Form 4)

    4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

    9/15/25 5:33:15 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Persky Marla sold $119,610 worth of shares (15,500 units at $7.72), decreasing direct ownership by 10% to 142,000 units (SEC Form 4)

    4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

    9/12/25 5:09:26 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $DSGN
    $PSTX
    $XERS
    Financials

    Live finance-specific insights

    View All

    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

    Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29

    9/29/25 4:05:49 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

    Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. "Total revenue in the second quarter increased almost 50%

    8/7/25 7:00:00 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

    Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login/LE9zwo3gmwDLA5JeSSHtiUIAhliB0lMHV58 After registering, a confirmation email

    7/31/25 7:30:00 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    $DSGN
    $PSTX
    $XERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $ANAB
    $DSGN
    $PSTX
    $XERS
    Leadership Updates

    Live Leadership Updates

    View All

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 4:00:05 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 9:24:47 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

    CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. "We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC® small molecules toward key clinical milestones," said Pratik Shah, Ph.D., chairperson an

    4/17/25 8:00:00 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services